Optimising TREATment for Severe Gram-Negative Bacterial Infections
Status:
RECRUITING
Trial end date:
2028-12-31
Target enrollment:
Participant gender:
Summary
TREAT-GNB is an innovative trial to expedite the evaluation of various antibiotic choices and treatment strategies for severe multidrug-resistant Gram-negative bacterial infections, specifically bloodstream and lower respiratory tract infections. This approach combines platform trial elements with adaptive clinical designs to streamline the evaluation of various treatment options and optimise resource utilisation. The overall aim of the TREAT-GNB platform trial is to identify interventions that improve survival in patients with severe infections due to Gram-negative bacteria.
In the CR-GNB silo of TREAT-GNB, the primary objective is to quantify the effect on all-cause mortality at 28 days of a range of interventions in patients with bloodstream infections, ventilator-associated pneumonia, and hospital-acquired pneumonia caused by CR-GNB.
Phase:
PHASE4
Details
Lead Sponsor:
National University of Singapore
Collaborators:
European Clinical Research Alliance for Infectious Diseases (ECRAID) The University of Queensland
Treatments:
avibactam, ceftazidime drug combination Aztreonam Cefiderocol ceftolozane, tazobactam drug combination Colistin Fosfomycin Meropenem meropenem and vaborbactam Polymyxin B Sulbactam